SLGL Stock Analysis: Sol-Gel Technologies Ltd
Sol-Gel Technologies Ltd., a pharmaceutical firm currently in its clinical development phase, specializes in the creation and market introduction of skin-applied medications. These products leverage the company's distinctive microencapsulation technology, with their primary development and commercialization activities centered in Israel. Sol-Gel's pipeline features several key candidates. Twyneo, an innovative, non-antibiotic topical cream designed for once-daily application, has successfully concluded Phase III tr
- Latest close
- $66.85
- 20-day change
- -7.88%
- Trend state
- LEAN BULL
- Classification
- Healthcare · Biotechnology
Market context
Sol-Gel Technologies Ltd moved -7.88% over the latest 20-session window. BullRecon currently classifies the broader setup as LEAN BULL.
Latest report
The latest cached company filing period (FY2025 · $3.8M revenue · -$6.1M net income) is used alongside annual and quarterly history. Values remain tied to their reported period.
Six-dimension read
Health is currently the strongest dimension at 5.4/6, while Value is the lowest at 1.3/6. Scores are comparative research signals, not forecasts.